John Theurer Cancer Center Participating in Early-Phase Study of Immunotherapy-Boosting Treatment
Hackensack Meridian HealthInvestigators at John Theurer Cancer Center at Hackensack University Medical Center in New Jersey are participating in a first-in-patients clinical trial assessing VE800, a novel bacteria-containing therapy, in combination with the immunotherapy drug nivolumab. Laboratory research has suggested that VE800 may enhance the effectiveness of drugs like nivolumab.